MBRX - Moleculin Biotech's annamycin brings 100% survival rate in osteosarcoma lung metastases in animals

Moleculin Biotech (MBRX) announces that a preclinical study in animals demonstrated a potentially significant therapeutic benefit of Annamycin against metastatic osteosarcoma.In addition to the preclinical study results announced on February 2, the survival rate for Annamycin-treated animals was 100%, compared with only 10% for untreated animals, while the study continues as of day 130. Annamycin is a "next generation" anthracycline that has shown in animal models to accumulate in lungs at up to 34 times the level of doxorubicin, resulting in 100% survival rate in this most recent osteosarcoma lung metastases study.Lack of cardiotoxicity in human trials for treatment of acute myeloid leukemia was also seen. Also, the FDA has granted Orphan Drug Designation for Annamycin in soft tissue sarcomas.Shares up 3% premarket.

For further details see:

Moleculin Biotech's annamycin brings 100% survival rate in osteosarcoma lung metastases in animals